Fosigotifator depression study is terminated after enrolling 20 participants

Calico/Fosigotifator (ABBV-CLS-7262)

AbbVie terminated its fosigotifator Phase 1b study in major depressive disorder on September 23, 2025, after enrolling 20 participants. The drug continues in Phase 1b/2 trials for vanishing white matter disease.

• Phase 1b randomized, double-blind, placebo-controlled trial in MDD terminated by company decision after 20 enrollments.
• Termination reflects broader shift at AbbVie away from small-molecule CNS programs toward other modalities.
• Development continues for VWM disease, the rare pediatric indication granted Breakthrough Therapy Designation in June 2026.